Article
Oncology
Lora Hamuro, Zheyi Hu, Julie Passarell, Heather Barcomb, Joshua Zhang, Shay Goldstein, Akintunde Bello, Amit Roy, Li Zhu
Summary: A benefit:risk assessment was conducted using modeling and simulation of clinical trial data to evaluate the less-frequent dosing regimen of nivolumab and cabozantinib. The results showed comparable efficacy and safety between different dosing regimens.
CLINICAL CANCER RESEARCH
(2022)
Article
Dermatology
Matthias Augustin, Kristian Reich, Paul Yamauchi, Andreas Pinter, Jerry Bagel, Swapnil Dahale, Ruquan You, Gerard Bruin, Jimena Djimopoulos, Bertrand Paguet, Pascal Charef, Manmath Patekar, Deborah Keefe
Summary: Secukinumab 300 mg every 2 weeks demonstrated superior and sustained efficacy compared with every 4 weeks in patients with moderate-to-severe plaque psoriasis who had a higher bodyweight. Uptitration to the every 2 weeks regimen provided additional benefits for nonresponders.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Review
Oncology
Carsten Bokemeyer, Fortunato Ciardiello, Olivier Dubreuil, Joel Guigay, Stefan Kasper, Per Pfeiffer, Carmine Pinto, Kensei Yamaguchi, Takayuki Yoshino, Christoph Zielinski, Regina Esser, Josep Tabernero
Summary: The every 2 weeks dosing schedule of cetuximab has been approved for use in patients with colorectal cancer and head and neck cancer. Studies have shown similar clinical benefits and side effects compared to the weekly dosing schedule, making it a convenient alternative.
Article
Clinical Neurology
Helmut Butzkueven, Ludwig Kappos, Tim Spelman, Maria Trojano, Heinz Wiendl, Ray Su, Shirley Liao, Robert Hyde, Stephanie Licata, Pei-Ran Ho, Nolan Campbell
Summary: This study, using propensity score-matched cohorts from the Tysabri Observational Program, demonstrates that the effectiveness of natalizumab is maintained in patients who switch from every-4-week (Q4W) dosing to every-6-week (Q6W) dosing after more than 1 year of treatment. Annualized relapse rates, probability of remaining relapse free, and safety outcomes did not differ significantly between Q6W and Q4W patients.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2021)
Article
Gastroenterology & Hepatology
Mathurin Fumery, Laurent Peyrin-Biroulet, Stephane Nancey, Romain Altwegg, Cyrielle Gilletta, Pauline Veyrard, Guillaume Bouguen, Stephanie Viennot, Florian Poullenot, Jerome Filippi, Anthony Buisson, Anne Bozon, Franck Brazier, Lieven Pouillon, Bernard Flourie, Lucile Boivineau, Laurent Siproudhis, David Laharie, Xavier Roblin, Momar Diouf, Xavier Treton
Summary: In this multicentre study, two-thirds of patients recaptured response following treatment intensification with ustekinumab 90 mg every 4 weeks.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Oncology
Nandini S. Menon, Vanita Noronha, Vijay Maruti Patil, Amit Joshi, Atanu Bhattacharjee, Devanshi Kalra, Sarbani Ghosh Laskar, Vijayalakshmi Mathrudev, Kavita Nawale, Arati S. Bhelekar, Kumar Prabhash
Summary: This study found that the use of once-every-3-weeks cisplatin with radiation did not have a negative impact on the quality of life for patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC), compared to once-a-week cisplatin. However, there were significant differences in the scales of constipation, reduced sexuality, and financial difficulty between the two treatment arms.
Article
Oncology
C. Le Tourneau, H. Becker, R. Claus, E. Elez, F. Ricci, R. Fritsch, Y. Silber, A. Hennequin, J. Tabernero, G. Jayadeva, D. Luedtke, M. He, N. Isambert
Summary: This study evaluated the efficacy and tolerability of BI 836880 in patients with metastatic solid tumors. The results demonstrate that BI 836880 is feasible and showed partial responses in some patients.
Article
Pharmacology & Pharmacy
Ye Xiong, Tomoyuki Mizuno, Ruben Colman, Jeffrey Hyams, Joshua D. Noe, Brendan Boyle, Yi-Ting Tsai, Min Dong, Kimberly Jackson, Nieko Punt, Michael J. Rosen, Lee A. Denson, Alexander A. Vinks, Phillip Minar
Summary: The study identified blood biomarkers for rapid clearance and exposure targets of infliximab in pediatric Crohn's disease. Higher AUC during induction was associated with better treatment outcomes and lower surgery rates for patients.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Oncology
Stefan Kasper, Caroline Foch, Diethelm Messinger, Regina Esser, Francois-Xavier Lamy, Vivien Rothe, Wenfeng Chen, Ann-Lii Cheng, Magali Rouyer, Thomas Brodowicz, Christoph Zielinski
Summary: The study found that cetuximab 500 mg/m(2) administered every 2 weeks was noninferior to the approved dose of 400 mg/m(2) followed by 250 mg/m(2) once weekly for overall survival in patients with RAS wild-type metastatic colorectal cancer. Additionally, the Q2W regimen showed better overall response rate and rates of lung/liver metastases resection compared to the Q1W regimen. No significant differences were observed in the occurrence rate of serious adverse events between the two groups.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Dermatology
Xi-Bei Chen, Yu-Xin Zheng, Li-Ran Ye, Xue-Yan Chen, Xiao-Yong Man
Summary: This study investigated the feasibility, efficacy, and safety of gradually increasing the secukinumab dosing interval in patients with moderate-to-severe psoriasis. The results showed that a majority of patients achieved PASI 75 improvement at week 36 after using the drug.
DERMATOLOGIC THERAPY
(2022)
Article
Oncology
Nobuyuki Katakami, Takashi Nishimura, Yu Hidaka, Akito Hata, Kazumi Nishino, Masahide Mori, Tomonori Hirashima, Naoto Takase, Toshihiko Kaneda, Hisashi Ohnishi, Satoshi Morita, Yukimasa Hatachi
Summary: The optimal dosing interval of Zoledronic acid (ZA) for lung cancer patients with bone metastases is uncertain. However, this study found that an eight-week ZA interval does not increase the risk of skeletal-related events in these patients.
Article
Medicine, General & Internal
Charles C. Wykoff, Francis Abreu, Anthony P. Adamis, Karen Basu, David A. Eichenbaum, Zdenka Haskova, Hugh Lin, Anat Loewenstein, Shaun Mohan, Ian A. Pearce, Taiji Sakamoto, Patricio G. Schlottmann, David Silverman, Jennifer K. Sun, John A. Wells, Jeffrey R. Willis, Ramin Tadayoni
Summary: This study demonstrates the efficacy and safety of faricimab in patients with diabetic macular edema. Treatment with faricimab every 8 weeks or personalized treatment interval dosing achieved non-inferiority and had good tolerability.
Article
Nutrition & Dietetics
Mia Bendix, Anders Dige, Soren Peter Jorgensen, Jens Frederik Dahlerup, Bo Martin Bibby, Bent Deleuran, Jorgen Agnholt
Summary: Seven-week high-dose vitamin D treatment reduces the need for later infliximab dose escalation and decreases inflammatory markers in patients with active Crohn's disease.
Article
Pharmacology & Pharmacy
Ih Chang, Kumar Kandadi Muralidharan, Nolan Campbell, Pei-Ran Ho
Summary: The study investigated the efficacy of extended-interval dosing of natalizumab in patients switching from every-4-week dosing, finding that every-5-week or every-6-week dosing may maintain efficacy, particularly in patients with body weights <80 kg. However, efficacy of natalizumab decreases as dosing intervals and body weight increase. Model-based simulations were partially validated in independent clinical studies, showing similar outcomes to those predicted by the models.
JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Clinical Neurology
John Foley, Kuangnan Xiong, Tammy Hoyt, Carol M. Singh, Evan Riddle, Carl de Moor, Tatiana Plavina, Nolan Campbell
Summary: This study aimed to compare levels of sNfL in patients with MS who switched from natalizumab every 4 weeks (Q4W) to extended interval dosing (EID) and patients who remained on Q4W dosing. The results showed no significant difference in sNfL levels between patients who switched to EID and those who stayed on Q4W dosing, suggesting that the effectiveness of natalizumab is maintained in patients who switch to EID.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Letter
Gastroenterology & Hepatology
Joshua Quan, Christopher Ma, Remo Panaccione, Lindsay Hracs, Nastaran Sharifi, Michelle Herauf, Ante Makovinovic, Stephanie Coward, Joseph W. Windsor, Lea Caplan, Richard J. M. Ingram, Jamil N. Kanji, Graham Tipples, Jessalyn K. Holodinsky, Charles N. Bernstein, Douglas J. Mahoney, Sasha Bernatsky, Eric Benchimol, Gilaad G. Kaplan
Article
Gastroenterology & Hepatology
Pauline Riviere, Caitlyn Kanters, Gauthier Pellet, Alexander Ni, Marianne Hupe, Nesrine Aboulhamid, Florian Poullenot, Alain Bitton, Frank Zerbib, Peter L. Lakatos, Waqqas Afif, David Laharie, Talat Bessissow
Summary: This study aimed to compare the efficacy of anti-tumor necrosis factor agents and ustekinumab in patients with Crohn's disease. The results showed that anti-tumor necrosis factor agents as first-line biological therapy were associated with higher response rates at 3 months compared to ustekinumab.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Moran Livne-Margolin, Daniel Ling, Shani Attia-Konyo, Chaya Mushka Abitbol, Ola Haj-Natour, Bella Ungar, Shomron Ben-Horin, Uri Kopylov
Summary: This study compared the effectiveness of vedolizumab and ustekinumab in treating extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) patients, and found no significant difference between the two in terms of EIM treatment.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Lorant Gonczi, Laszlo Lakatos, Zsuzsanna Kurti, Petra Golovics, Tunde Pandur, Gyula David, Zsuzsanna Erdelyi, Istvan Szita, Peter L. Lakatos
Summary: This study conducted a prospective study on Crohn's disease patients in Hungary and found a high incidence rate, reflecting the era of biologic therapy in treatment strategies. The progression of disease behavior was low and long-term surgery rates had decreased.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Joana Torres, Maria Chaparro, Mette Julsgaard, Konstantinos Katsanos, Zuzana Zelinkova, Manasi Agrawal, Sandro Ardizzone, Marjo Campmans-Kuijpers, Gabriele Dragoni, Marc Ferrante, Gionata Fiorino, Emma Flanagan, Catarina Frias Gomes, Ailsa Hart, Charlotte Rose Hedin, Pascal Juillerat, Annemarie Mulders, Par Myrelid, Aoibhlinn O'Toole, Pauline Riviere, Michael Scharl, Christian Philipp Selinger, Elena Sonnenberg, Murat Toruner, Jantien Wieringa, C. Janneke Van der Woude
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Jurij Hanzel, Peter Bossuyt, Valerie Pittet, Mark Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Johan Burisch, Salvatore Leone, Roberto Saldana, Filip Baert, Uri Kopylov, Susanna Jaghult, Michel Adamina, Naila Arebi, Krisztina Gecse
Summary: This study aimed to develop a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Candidate outcomes and outcome measures were identified through a systematic review and a modified Delphi consensus process. The international panel agreed on the final core outcome set, which will facilitate the synthesis and generation of real-world evidence.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Hannah Gordon, Livia Biancone, Gionata Fiorino, Konstantinos H. Katsanos, Uri Kopylov, Eman Al Sulais, Jordan E. Axelrad, Karthiha Balendran, Johan Burisch, Lissy de Ridder, Lauranne Derikx, Pierre Ellul, Thomas Greuter, Marietta Iacucci, Caroline Di Jiang, Christina Kapizioni, Konstantinos Karmiris, Julien Kirchgesner, David Laharie, Triana Lobaton, Tamas Molnar, Nurulamin M. Noor, Rohit Rao, Simone Saibeni, Michael Scharl, Stephan R. Vavricka, Tim Raine
JOURNAL OF CROHNS & COLITIS
(2023)
Editorial Material
Gastroenterology & Hepatology
Paolo Angelo Cortesi, Gionata Fiorino, Lorenzo Giovanni Mantovani, Silvio Danese
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Luca Massimino, Orazio Palmieri, Amanda Facoetti, Davide Fuggetta, Salvatore Spano, Luigi Antonio Lamparelli, Silvia D'Alessio, Stefania Cagliani, Federica Furfaro, Ferdinando D'Amico, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Daniele Noviello, Anna Latiano, Fabrizio Bossa, Tiziana Latiano, Alessandra Pirola, Luca Mologni, Rocco Giovanni Piazza, Danilo Abbati, Francesco Perri, Chiara Bonini, Laurent Peyrin-Biroulet, Alberto Malesci, Vipul Jairath, Silvio Danese, Federica Ungaro
Summary: This study found that the virome-associated protein encoded by the hepatitis B virus (HBx) is detected in about 45% of patients with ulcerative colitis (UC) and is associated with UC progression. Experimental findings showed that HBx induces colonic inflammation and its silencing reverses the colitis phenotype. HBx acts as a transcriptional regulator in epithelial cells, leading to barrier leakage and altering mucosal immunity. This study provides a new perspective on targeted treatments for the virome composition of the gut microbiota.
Article
Gastroenterology & Hepatology
Dan Carter, Ahmed Albshesh, Carmi Shimon, Batel Segal, Alex Yershov, Uri Kopylov, Adele Meyers, Rafael Y. Brzezinski, Shomron Ben Horin, Oshrit Hoffer
Summary: We developed a machine-learning module based on a pretrained convolutional neural network that accurately recognizes bowel wall thickening on intestinal ultrasound images in Crohn's disease. This module can assist inexperienced operators in using intestinal ultrasound, simplifying the diagnosis of inflammatory bowel disease.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Livia Lontai, Zsuzsanna Kurti, Lorant Gonczi, Nora Komlodi, Fruzsina Balogh, Akos Ilias, Peter L. Lakatos
Summary: This study aimed to evaluate the value of objective disease monitoring in inflammatory bowel disease. The results showed that objective monitoring strategy led to early optimization of medical therapy and frequent specialist follow-up visits, which improved patient outcomes.
TURKISH JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Panu Wetwittayakhlang, Christine Verdon, Michael Starr, Gustavo Drugg Hahn, Petra A. Golovics, Talat Bessissow, Waqqas Afif, Gary Wild, Alain Bitton, Peter L. Lakatos
Summary: This study aimed to investigate small bowel mucosal healing and clinical efficacy of adalimumab therapy by video capsule endoscopy in patients with endoscopically active upper gastrointestinal Crohn's disease. The results showed that adalimumab induced endoscopic healing and clinical remission in approximately half of the patients.
TURKISH JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Medicine, General & Internal
Lena Royston, Stephane Isnard, Carolina A. Berini, Simeng Bu, Peter L. Lakatos, Talat Bessissow, Nicolas Chomont, Marina Klein, Bertrand Lebouche, Alexandra de Pokomandy, Nadine Kronfli, Cecilia T. Costiniuk, Rejean Thomas, Cecile Tremblay, Guy Boivin, Jean-Pierre Routy
Summary: This study aims to assess whether letermovir, a novel anti-CMV drug, can inhibit CMV subclinical replication in HIV patients receiving ART, and subsequently reduce CMV-associated gut damage and inflammation. The study will conduct a 14-week open-label, randomized, controlled clinical trial with 60 CMV-seropositive ART-treated HIV patients. The effects of letermovir on gut damage, microbial translocation, inflammation, and HIV reservoir size will be evaluated.
Meeting Abstract
Gastroenterology & Hepatology
P. Bacsur, P. Wetwittayakhlang, T. Resal, M. Rutka, T. Bessissow, W. Atif, A. Balint, A. Fabian, R. Bor, Z. Szepes, K. Farkas, P. L. Lakatos, T. Molnar
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Medicine, General & Internal
Reem Al-jabri, Panu Wetwittayakhlang, Peter L. Lakatos
Summary: Understanding the relationship between Inflammatory Bowel Disease (IBD) and pregnancy is crucial, and monitoring IBD activity during pregnancy involves various methods. Small Intestine Ultrasound (IUS) has gained popularity as a noninvasive and reliable option for monitoring. However, trained staff is necessary for optimal usage due to its technique-sensitive nature.
JOURNAL OF CLINICAL MEDICINE
(2023)